Clinical Trial Update: Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Rituxan and BEAM with autologous peripheral blood progenitor transplant in indolent lymphoma (Phase 1/Phase 2) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: University of Nebraska | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED